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CLINICAL SCIENCE
Increased IgE serum levels are unrelated to allergic
and parasitic diseases in patients with juvenile
systemic lupus erythematosus
Bernadete L. Liphaus, Adriana A. Jesus, Clovis A. Silva, Antonio Coutinho, Magda Carneiro-Sampaio
Instituto da Crianc¸a (ICr) do Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Sa˜o Paulo/SP, Brazil.
OBJECTIVE: The aim of this study was to assess the IgE serum levels in juvenile systemic lupus erythematosus patients
and to evaluate possible associations with clinical and laboratory features, disease activity and tissue damage.
METHODS: The IgE serum concentrations in 69 consecutive juvenile systemic lupus erythematosus patients were
determined by nephelometry. IgG, IgM and IgA concentrations were measured by immunoturbidimetry. All patients
were negative for intestinal parasites. Statistical analysis methods included the Mann-Whitney, chi-square and
Fisher’s exact tests, as well as the Spearman rank correlation coefficient.
RESULTS: Increased IgE concentrations above 100 IU/mL were observed in 31/69 (45%) juvenile systemic lupus
erythematosus patients. The mean IgE concentration was 442.0¡163.4 IU/ml (range 3.5-9936.0 IU/ml). Fifteen of the
69 patients had atopic disease, nine patients had severe sepsis and 56 patients presented with nephritis. The mean
IgE level in 54 juvenile systemic lupus erythematosus patients without atopic manifestations was 271.6¡699.5 IU/ml,
and only nine of the 31 (29%) patients with high IgE levels had atopic disease. The IgE levels did not statistically
differ with respect to the presence of atopic disease, severe sepsis, nephritis, disease activity, or tissue damage.
Interestingly, IgE concentrations were inversely correlated with C4 levels (r = -0.25, p= 0.03) and with the SLICC/ACR-
DI score (r = -0.34, p= 0.005). The IgE concentration was also found to be directly correlated with IgA levels (r = 0.52,
p= 0.03).
CONCLUSIONS: The present study demonstrated for the first time that juvenile systemic lupus erythematosus
patients have increased IgE serum levels. This increase in IgE levels was not related to allergic or parasitic diseases.
Our results are in line with the hypothesis that high IgE levels can be considered a marker of immune
dysregulation.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex auto-
immune disease with respect to its underlying genetics, and
it is characterized by the disruption of immune tolerance,
leading to a hyperactive Th2 response, polyclonal activation
of B lymphocytes, immune-complex deposition, and tissue
damage (1-5). In SLE patients, the Th2 response is evidenced
by the significant production of interleukins (ILs) 4, 5, and
10, which is similar to the interleukin profile in patients with
allergic disorders (4-8).
Of note, the polyclonal activation of B lymphocytes in SLE
patients results in the production of autoantibodies, particu-
larly of the IgG and IgM classes, and, rarely, antinuclear IgE
autoantibodies and IgE immune complexes (1-4,7,9,10).
Indeed, IgE plays a central role in host immunity against
parasitic infections and in the pathogenesis of atopic diseases
(5,11). Recently, IgE has also been considered a biomarker for
immune dysregulation, as observed in patients with partial T
cell immunodeficiencies (5). To date, few studies have
evaluated the IgE levels in SLE patients (4,6,7). High total
IgE serum levels have been associated with disease activity
and nephritis in adult SLE patients (4,12-15). However, to our
knowledge, no studies have evaluated the association of IgE
with juvenile SLE (JSLE).
Therefore, the aim of this study was to assess total IgE
serum concentrations in JSLE patients and to evaluate
possible associations between increased IgE levels and
clinical and laboratory lupus features, disease activity and
tissue damage.
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METHODS
Sixty-nine consecutive patients diagnosed with JSLE
based on the American College of Rheumatology (ACR)
revised classification criteria were enrolled in this study
(16,17). At the onset of disease, all patients were younger
than 16 years of age. This study was approved by the local
ethics committee, and informed consent was obtained from
all patients/parents participating in the study. The exclu-
sion criteria included bacterial, viral, fungal or parasitic
infection at the time of study entry.
Clinical evaluation and treatment
Patients and parents were systematically inquired regard-
ing the following allergic manifestations: atopic dermatitis,
acute or chronic urticaria, allergic rhinitis, asthma, and drug
and food reactions. The presence of infection (recurrent
pyogenic infections, mycobacteriosis, fungal infections,
herpes zoster and/or severe sepsis) was also assessed.
Severe sepsis was defined according to the international
pediatric sepsis consensus conference definitions (18).
Medical records were evaluated for patients clinical
findings, which included cutaneous, hematological, renal,
musculoskeletal and neuropsychiatric manifestations. The
renal histologic class according to the World Health
Organization classification criteria was also registered (19).
Disease activity and disease-related tissue damage were
determined for each patient upon enrollment based on the
SLE Disease Activity Index 2K (SLEDAI 2K) and the
Systemic Lupus International Collaborating Clinics/ACR
Damage Index (SLICC/ACR-DI) scores, respectively (20-
22). Disease activity was arbitrarily defined as equivalent to
a SLEDAI 2K score$4.
All patients were prescribed glucocorticoid therapy, and
fifty-eight patients were taking one of the following
immunosuppressive agents: intravenous cyclophospha-
mide, azathioprine, methotrexate, or mycophenolate mofe-
til.
Laboratory evaluation
Total serum IgE concentrations were determined by
nephelometry (Dade Behring/Siemens, Deerfield, USA).
According to recommendations by the manufacturer and
several previous studies on IgE levels, the cut-off value for
an elevated IgE level was set at 100 IU/ml (23-26). Serum
IgG, IgM and IgA levels were determined by immunoturbi-
dimetry (Roche Diagnostics, Indianapolis, USA).
The following laboratory parameters were also analyzed:
complete blood cell count, urinalysis, and erythrocyte
sedimentation rate, determined using the Westergren
method; C reactive protein, determined by nephelometry;
and serum complement components C3 and C4, determined
by nephelometry. Serum levels of C1q were determined by
radial immunodiffusion. Antinuclear antibodies (ANAs)
were detected by indirect immunofluorescence in HEp-2
cells, and anti-dsDNA antibodies were determined by both
indirect immunofluorescence on Crithidia luciliae and by
quantitative ELISA.
Three consecutive stool samples were collected from each
patient. Stool analyses were performed by a blinded,
qualified technician by microscopic examination for the
detection of protozoan oocysts, cysts, helminthic eggs, and
larvae using techniques published by Faust et al., as well as
modified techniques published by Rugai and Lutz,
Hoffman, Pons and Janer.
Statistical analysis
Continuous variables were analyzed using a Mann-
Whitney test, and categorical variables were evaluated
using a chi-square or Fisher’s exact test, as appropriate
(27). Correlation analyses were performed using the
Spearman rank correlation coefficient (27). p-values ,0.05
were considered statistically significant.
RESULTS
The mean age of the patients upon enrollment was
15.8¡3.7 years, and 58 of the 69 patients were female. The
mean disease duration and age at disease onset were
6.9¡3.6 and 8.8¡3.3 years, respectively. The clinical and
laboratory characteristics of the JSLE patients are presented
in Table 1.
Allergic manifestations were reported by 15 (21.7%) JSLE
patients; specifically, three had atopic dermatitis, nine
presented with allergic rhinitis and/or asthma and three
presented with both respiratory and cutaneous allergic
features. Severe sepsis was observed in nine (13%) patients.
Fifty-six (81.2%) patients presented with nephritis, 39 of
whom underwent renal biopsy. Of the patients who under-
went renal biopsy, seven (17.9%) had focal proliferative
nephritis (class III), ten (25.6%) had diffuse proliferative
nephritis (class IV), and 17 (43.6%) had membranous
nephritis (class V).
The total IgE concentrations in the JSLE patients ranged
from 3.5 to 9936.0 IU/ml. Increased IgE concentrations
($100 IU/ml) were observed in 31 of the 69 (45%) patients,
and the mean IgE level was 442.0¡163.4 IU/ml (Figure 1).
The mean IgG, IgM and IgA concentrations were
1387.9¡557.4, 115.8¡59.0 and 207.7¡152.3 mg/dl, respec-
tively.
The IgE levels ranged from 6.1 to 9936.0 IU/ml in the
JSLE patients with atopic disease, 3.5 to 9936.0 IU/ml in
patients with active disease (SLEDAI 2K$4), 3.5 to
2934.0 IU/ml in patients with severe sepsis and 3.5 to
4920.0 IU/ml in patients with nephritis. In JSLE patients
without atopic manifestations (n = 54), the mean IgE level
Table 1 - Clinical and laboratory findings in 69 patients
with juvenile systemic lupus erythematosus.
Clinical and laboratory features N˚ (%)
Cutaneous manifestation 69 (100)
Hematologic alterations 64 (92.8)
Musculoskeletal disorder 55 (80.9)
Neuropsychiatric disease 34 (49.3)
Nephritis/Renal biopsy 56 (81.2)/39 (56.5)
Renal histologic class I or II 4/39 (10.3)
Renal histologic class III 7/39 (17.9)
Renal histologic class IV 10/39 (25.6)
Renal histologic class V 17/39 (43.6)
Renal histologic class VI 1/39 (2.6)
Atopic manifestations 15 (21.7)
Severe sepsis 9 (13.0)
FAN+ 69 (100)
Anti-dsDNA+($50 IU/ml) 26 (37.7)
SLEDAI 2K$4 45 (65.2)
SLICC/ACR-DI$1 38 (55.1)
IgE$100 IU 31 (45.0)
IgE.1000 IU 4 (6.0)
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was 271.6¡699.5 IU/ml. Nine of the 31 patients (29%) with
high IgE levels had atopic disease. The mean IgE level in 18
patients with severe active disease (SLEDAI 2K $10) was
371.7¡691.1, which was more than two-fold higher than
that in the 12 patients with an SLEDAI 2K score of zero
(133.6¡171.2, p= 0.4). Thirty-four patients had severe
nephritis (renal histologic class III, IV, or V), with IgE
concentrations ranging from 3.5 to 4920.0 IU/ml. Of note,
four patients had IgE values.1000 IU/ml, and one of these
patients presented with a primary C1q deficiency and atopic
manifestations. IgE serum levels did not statistically differ
with respect to the presence of atopic manifestations, severe
sepsis, nephritis, severe nephritis, disease activity, or tissue
damage (p.0.05) (Table 2).
Additionally, IgE serum concentrations were inversely
correlated with C4 levels (r = -0.25, p= 0.03) and with the
patient SLICC/ACR-DI scores (r = -0.34, p= 0.005). The IgE
levels were also directly correlated with patient IgA levels
(r = 0.52, p= 0.03) (Figure 2). No correlation was observed
between IgE serum levels and C3 levels, IgG levels, IgM
levels, anti-dsDNA levels or SLEDAI 2K scores.
DISCUSSION
The present study showed that JSLE patients have an
increased serum IgE concentration regardless of the
presence of atopic manifestations or parasitic disease.
SLE pathogenesis is complex, and there remain contro-
versies concerning the involvement of immunoglobulin E in
the pathogenesis of the disease (1-5). The dysregulation of
immune tolerance results in aberrant Th2 responses and
polyclonal activation of B lymphocytes along with the
production of autoantibodies, including those of IgE isotype
(1-5,10). The human Th2 immune response, characterized by
the significant production of IL-4, IL-5, IL-10, and IgE, is
mainly observed in atopic diseases and in some parasitic
infections; however, elevated IgE production has also been
observed in patients with partial T cell immunodeficiencies
and autoimmune diseases (5,7,8).
Although IgE synthesis is tightly controlled by regulatory T
cells, B cells, and cytokines, the role of immunoglobulin E in
autoimmune diseases has not been fully elucidated (11). The
most striking observation reported in the literature is that
elevated IgE production and allergic and autoimmune
manifestations frequently occur in patients with partial T cell
immunodeficiencies even though elevated IgE levels and
autoimmune and inflammatory diseases are traditionally
associated with hyperactivity of the adaptive immune system
(5). Moreover, mouse models have recently highlighted that
an increased IgE level frequently accompanies different
partial T cell immunodeficiencies that result in autoimmunity
(5). Taken together, these observations suggest that IgE levels
increase when there is an imbalance between the immuno-
genic and tolerogenic signals in effector T cells; thus, elevated
IgE levels can be considered a biomarker of immune
dysregulation (5).
Although some authors have postulated that IgE is not
related to connective tissue disease pathogenesis, others
have claimed that IgE plays an essential role in connective
tissue disorders (7,28). The latter authors state that, through
the release of vasoactive mediators from basophils and mast
Figure 1 - IgE serum concentrations in 69 patients with juvenile systemic lupus erythematosus. Individual values were plotted in the
graph with normal values for IgE obtained from a standard curve previous established21. White circles represent patients WITH atopic
manifestations, while black circles represent patients WITHOUT atopic manifestations.
Table 2 - Total IgE serum concentrations (IU/ml) in 69
patients with juvenile systemic lupus erythematosus
(JSLE) according to clinical features, disease activity and
tissue damage.
Clinical Feature (N˚)
Present
Mean¡SD
Absent
Mean¡SD p-value
Atopic disease
(15)
1055.4¡2565.5 271.6¡699.5 0.22
Severe sepsis (9) 460.5¡965.5 439.2¡1413.2 0.73
Nephritis (56) 339.3¡776.8 884.6¡2722.7 0.73
Severe nephritis (34) 311.4¡837.7 896.3¡1302.3 0.80
SLEDAI 2K$4 (45) 614.9¡1657.8 117.8¡147.9 0.38
SLICC/ACR-DI$1 (38) 280.5¡540.0 639.9¡1934.7 0.54
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cells, IgE can cause increased vasopermeability, which may
be important in causing the deposition of circulating
immune complexes in glomerulonephritis pathogenesis
(28,29). The demonstration of increased IgE serum levels
in SLE patients with renal involvement and the detection
of IgE immune complex deposition in renal biopsies
further implicate IgE in the pathogenesis of lupus
nephritis (13,29,30). High IgE levels have also been
reported in adult SLE patients without nephritis, suggest-
ing that IgE may have a role in SLE disease and not only
in nephritis (4,12,14,15,31,32). Furthermore, antinuclear
and anti-DNA autoantibodies of the IgE isotype were
observed in adult SLE patients, and these IgE autoanti-
bodies did not correlate with the serum IgE concentration
(4,9,10,33). Anti-IgE IgG autoantibodies have also been
observed in SLE patients with lymphoadenopathy, articu-
lar involvement and anti-DNA antibodies (9). In addition,
increased IgE serum levels were observed in children of
mothers with lupus, regardless of the presence of allergic
disease in the mothers (34). Another study showed
elevated IgE levels in male SLE patients compared with
female patients (35). To the best of our knowledge, this
was the first study to demonstrate increased IgE levels in
JSLE patients.
SLE and allergic disorders share certain immunological
abnormalities (6,7) because the prevalence of IgE-mediated
and/or IgE-associated disorders, such as allergic reactions
to drugs, atopic dermatitis, asthma, allergic rhinitis and
allergic conjunctivitis, has been reported to be elevated in
patients with lupus (6,12,36,37). In contrast, recent studies
observed a similar prevalence of IgE-related disorders in
SLE subjects compared with patients without SLE (30,38-41).
In our study, 15 (21.7%) JSLE patients had at least one
respiratory and/or cutaneous allergic manifestation, which
is similar to the rate of atopic disorders found in healthy
subjects (40,42).
The current study showed that JSLE patients harbor
higher IgE concentrations in a manner independent of the
presence of allergic disease. Our observations are in line
with recent reports stating that patients with lupus are not
at an increased risk of IgE-mediated allergic disorders.
However, our observations differ from those of previous
studies reporting evidence of an increased incidence of
atopic conditions in SLE patients (12,13,38,41).
We also observed increased IgE serum levels in JSLE
patients independent of the presence of parasitic infections.
However, the IgE serum concentrations varied widely,
which may be due to differences in environment- and
patient-specific factors, such as contact with antigens, race,
gender and age. Witting et al. (24) showed that an IgE level
of 100 IU/ml is the upper-limit cutoff for elevated IgE
diagnostic sensitivity and specificity for all patient cohorts.
Thus, one possible limitation of this study is the lack of
comparison with age- and gender-matched healthy controls.
Regarding lupus activity, patients with severe active
disease (SLEDAI 2K $10) had IgE levels at least two times
higher than the IgE levels of patients with inactive disease,
although this difference was not statistically significant.
Interestingly, IgE concentrations correlated inversely with
C4 levels, which could suggest that the complement
cascade was activated and its components were consumed,
as shown by the reduction of C4 levels, which is also
considered a marker of disease activity. The latter state-
ment that IgE levels could be a marker of disease activity
requires further investigation because the correlation
between IgE and C4 levels was relatively weak. Although
serum IgE levels have been reported to vary according to
disease activity in adult SLE patients (14,15,31,39), our
findings could not confirm this correlation in a definitive
manner in patients with JSLE.
Interestingly, IgE serum concentrations were inversely
correlated with SLICC/ACR-DI scores, suggesting a pro-
tective role for increased IgE levels. This finding is contrary
to current knowledge that patients with active disease have
high IgE levels and are consequently at a higher risk of
organ damage. In addition to the observed direct correlation
between IgE and IgA serum levels, the inverse relationship
between IgE levels and SLICC/ACR-DI scores supports the
hypothesis that increased IgE levels can be considered a
marker of immune dysregulation, which may be important
in the generation of immune complexes.
Lupus nephritis, which has various histological patterns
and variable clinical outcomes, is one of the most important
SLE-associated morbidities. Although the pathogenic
mechanism in each histological type of nephritis remains
unclear, some findings point to a role for both Th1 and Th2
immune responses in renal damage (7,28). Th1 cytokines
have been related to diffuse lupus nephritis, while Th2
cytokines have been associated with membranous lupus
nephritis (7,13,28-30). In the present study, 81.2% of the JSLE
patients had lupus nephritis, and IgE levels $100 UI/ml
were observed in 36.2% of these patients. However, the
Figure 2 - Correlations between IgE serum concentrations, C4 levels and SLICC/ACR-DI score in patients with juvenile systemic lupus
erythematosus.
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mean IgE levels were similar in patients with and without
nephritis, as well as in patients with severe renal disease. This
observation is in contrast with the published works with adult
SLE patients, which showed a significant correlation between
serum IgE concentration and nephritis activity, and previous
reports, which showed that IgE renal deposits in lupus patients
correlate with a poor prognosis (13,30,39).
All patients with JSLE were taking glucocorticoids, and
the down-regulation of allergic inflammation could have
been associated with the use of this medication, as
glucocorticoids can increase IL-10 gene transcription and
decrease both IL-4 and IL-5 gene transcription (43).
Finally, despite the variety of factors that can influence
IgE production, the present study demonstrated for the first
time that JSLE patients have higher IgE concentrations,
suggesting that increased IgE levels could play a role in
lupus pathogenesis. However, the specific mechanisms
underlying the elevation of IgE levels in children with
lupus remain to be clarified, and further studies are needed.
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